Mobasheri, A., Mahmoudian, A., Kalvaityte, U. et al. A White Paper on Collagen Hydrolyzates and Ultrahydrolyzates: Potential Supplements to Support Joint Health in Osteoarthritis?. Curr Rheumatol Rep 23, 78 (2021). https://doi.org/10.1007/s11926-021-01042-6
A white paper on collagen hydrolyzates and ultrahydrolyzates : potential supplements to support joint health in osteoarthritis?
|Author:||Mobasheri, Ali1,2,3,4,5; Mahmoudian, Armaghan6; Kalvaityte, Ursule2;|
1Research Unit of Medical Imaging, Physics and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland
2Department of Regenerative Medicine, State Research Institute, Centre for Innovative Medicine, Vilnius, Lithuania
3Departments of Orthopedics, Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
4Department of Joint Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, Guangdong, China
5World Health Organization Collaborating Center for Public Health Aspects of Musculoskeletal Health and Aging, Université de Liège, Liège, Belgium
6Department of Clinical Sciences Lund, Orthopaedics, and Skeletal Biology, Clinical Epidemiology Unit, Lund University, Lund, Sweden
7School of Human Nutrition, McGill University, 21,111 Lakeshore, Ste. Anne de Bellevue, QC, H9X 3V9, Canada
8Hospital Universitário Clementino Fraga Filho, Department of Traumatolgy and Orthopedics of Medical Faculty of Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
9Santa Casa Sao Paulo, Sao Paulo, SP, Brazil
10Colorado Program for Musculoskeletal Research, Department of Orthopedics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
11Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, The Netherlands
12Department of Orthopaedic Surgery, CAPHRI School for Public Health and Primary Care, Maastricht University Medical Centre, Maastricht, The Netherlands
13Divisão de Medicina Física, Instituto de Ortopedia e Traumatologia do Hospital das Clinicas da Faculdade de Medicina da, Universidade de São Paulo (FMUSP), São Paulo, SP, Brazil
|Online Access:||PDF Full Text (PDF, 2 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2021120959894
|Publish Date:|| 2021-12-09
Purpose of Review: Osteoarthritis (OA) is the most common forms of arthritis in the general population, accounting for more pain and functional disability than any other musculoskeletal disease. There are currently no approved disease modifying drugs for OA. In the absence of effective pharmacotherapy, many patients with OA turn to nutritional supplements and nutraceuticals, including collagen derivatives. Collagen hydrolyzates and ultrahydrolyzates are terms used to describe collagens that have been broken down into small peptides and amino acids in the presence of collagenases and high pressure.
Recent Findings: This article reviews the relevant literature and serves as a White Paper on collagen hydrolyzates and ultrahydrolyzates as emerging supplements often advertised to support joint health in OA. Collagen hydrolyzates have demonstrated some evidence of efficacy in a handful of small scale clinical trials, but their ability to treat and reverse advanced joint disease remains highly speculative, as is the case for other nutritional supplements.
Summary: The aim of this White Paper is to stimulate research and development of collagen-based supplements for patients with OA and other musculoskeletal diseases at academic and industrial levels. This White Paper does not make any treatment recommendations for OA patients in the clinical context, but simply aims to highlight opportunities for scientific innovation and interdisciplinary collaboration, which are crucial for the development of novel products and nutritional interventions based on the best available and published evidence.
Current rheumatology reports
|Type of Publication:||
A2 Review article in a scientific journal
|Field of Science:||
3121 General medicine, internal medicine and other clinical medicine
Open access funding provided by University of Oulu including Oulu University Hospital.
© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.